HER‑2, IHC, without Interpretation
Use
This immunohistochemical (IHC) assay evaluates HER‑2 (c‑erbB‑2) protein expression in formalin‑fixed, paraffin‑embedded tumor tissue—specifically for assessment in invasive primary or metastatic breast or gastric cancers. It serves as an aid in identifying patients potentially eligible for HER‑2 targeted therapy, such as trastuzumab, by detecting overexpression of the HER‑2 protein.
Special Instructions
Submit a tumor paraffin block or five 4‑micron unstained sections on Poly‑L‑Lysine or Silane coated slides. Include an H&E slide and a copy of the pathology report. Do not use paper labels with adhesive backing on slides; label with pencil or xylene‑resistant pen on the frosted end. Specimen must be fixed in 10% neutral buffered formalin.
Limitations
Results may be affected if specimens are not fixed in 10% neutral buffered formalin or if fixation is inadequate (e.g., using Bouin’s or Zenker’s fixative, or insufficient fixation times). Interpretation is not part of the service—report provides staining results without interpretive commentary.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Five 4‑micron unstained sections (or tumor paraffin block)
Container
Poly‑L‑Lysine or Silane coated slides or paraffin block bag
Collection Instructions
Tumor paraffin block (formalin‑fixed only) or five 4‑micron unstained sections on Poly‑L‑Lysine or Silane coated slides; include H&E slide and pathology report; do not place paper labels—use pencil or xylene‑resistant pen on frosted end of slide.